.png){kind=icon}
.png){kind=icon}
Return
Pneumococcal meningitis among hospitalised children after introduction of pneumococcal conjugate vaccine in India: a sentinel hospital surveillance (2019–2022)
.png){kind=icon}
OA
AI
C
R
B
S
L
R
P
B
V
P
V
S
B
D
M
G
N
B
A
N
DOI：10.1016/j.lansea.2026.100790.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
In 2017 India introduced the 13-valent pneumococcal conjugate vaccine (PCV13; Prevenar 13®) in select high-burden sites and in 2021, transitioned to nationwide introduction of 10-valent PCV (PCV10-SII; PNEUMOSIL®). We examined data from a large sentinel paediatric meningitis surveillance network to assess early changes in pneumococcal meningitis among hospitalised children after introduction of pneumococcal vaccine.
Keywords:
Pneumococcal meningitis
Pneumococcal conjugate vaccine
Serotypes
PCV10
India
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
T
IF:
0
Papers:
93
Citations:
0
Organization
No organization information available